Investment Thesis
CEL SCI Corp is a pre-revenue or near-zero revenue biotech company with severe operational losses and negative cash flow, indicating it is not yet generating meaningful commercial activity. The company is burning cash at approximately $4M annually with only $6.3M in cash reserves, suggesting a finite runway of less than 2 years without additional capital raises. The distorted profitability ratios (positive margins despite negative absolute results) and persistent negative returns on equity and assets indicate a company in early-stage development with significant execution risk.
Strengths
- Adequate liquidity position with current ratio of 1.39x and $6.3M cash on hand
- Moderate leverage with debt-to-equity of 0.51x providing some financial flexibility
- Recent insider activity (4 Form 4 filings in 90 days) may indicate management confidence
Risks
- Severe cash burn of $4M annually with limited runway (less than 2 years at current burn rate)
- Revenue near zero (-$87.8K) with no evidence of commercial traction or product viability
- Persistent negative operating cash flow and lack of path to profitability visible in current operations
- Company operates in highly competitive biological products sector with long development timelines and high failure rates
- Negative returns on equity (-49.1%) and assets (-23.9%) indicate shareholder value destruction
Key Metrics to Watch
- Cash runway and burn rate trends (critical for survival)
- Revenue growth trajectory and any clinical trial milestones
- Operating cash flow improvement and path to profitability
- Capital raises and dilution (essential given cash burn)
- R&D spending efficiency and product pipeline advancement
Financial Metrics
Revenue
-87.8K
Net Income
-5.5M
EPS (Diluted)
$-0.68
Free Cash Flow
-4.0M
Total Assets
22.9M
Cash
6.3M
Profitability Ratios
Gross Margin
N/A
Operating Margin
6,115.6%
Net Margin
6,230.2%
ROE
-49.1%
ROA
-23.9%
FCF Margin
4,581.6%
Balance Sheet & Liquidity
Current Ratio
1.39x
Quick Ratio
1.19x
Debt/Equity
0.51x
Debt/Assets
51.3%
Interest Coverage
-61.01x
Long-term Debt
5.7M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-23T06:26:11.949628 |
Data as of: 2025-12-31 |
Powered by Claude AI